Articles tagged with Neurodegenerative Diseases
Researchers at UC San Diego have developed a CRISPR-based therapy that targets and destroys mutant RNA molecules causing Huntington's disease. The approach improved motor coordination and reduced toxic protein levels in mouse models, suggesting a potential new treatment direction.
An interdisciplinary team from Erlangen has found a new treatment for Huntington's disease by accelerating the degradation of a specific messenger molecule necessary for protein synthesis. This reduces the huntingtin level in patients, offering new hope for long-term implementation of RNA-modifying approaches for fatal diseases.
A new laboratory test can measure levels of amyloid beta oligomers in blood samples, detecting toxic proteins up to years before cognitive impairment. The test, SOBA, has shown promising results in identifying individuals at risk or incubating Alzheimer's disease.
Scientists have developed an AI method to pinpoint cells indicative of Alzheimer's disease based on DNA packing in mouse brain images, offering a potential early detection tool. This approach combines multi-scale imaging with artificial intelligence to identify biomarkers for aging-related diseases.
Early stage clinical studies confirm 40Hz sensory stimulation is safe, with no serious adverse effects. The therapy also showed significant neurological and behavioral benefits, including improved brain activity, reduced brain atrophy, and better sleep patterns.
A survey by UCI MIND found that media coverage of the FDA's decision made people less willing to volunteer for Alzheimer's pharmaceutical trials. The study highlights the powerful influence of media coverage on scientific research and emphasizes the need for diverse populations in clinical trials.
The study uses 3D electron microscopy and live cell imaging to observe molecular tethers between organelles. These dynamic structures are constantly binding and unbinding, altering contact site configuration in response to cellular changes.
A new survey by the European Federation of Dietitians supports moderate coffee consumption as having clear health benefits, including improved alertness and sports performance. The study involved 585 dietitians from across 26 European countries.
A new hallmark of ALS has been identified, revealing that loss of the RNA processing protein SFPQ leads to motor neuron degeneration. Defective mRNAs accumulate in axons and interfere with normal function, pointing to a possible new target for therapy.
Researchers identified USP7 as a novel cyclin F-interacting protein that stabilizes cyclin F protein. The study also found that USP7 regulates cyclin F mRNA, with pharmacological inhibition resulting in downregulation of cyclin F mRNA.
A new study published in the journal Nature has identified medin as a key player in Alzheimer's therapies. Medin, a protein that accumulates in the blood vessels of the brain, promotes vascular pathology and cognitive decline. The researchers hope to develop a treatment targeting medin to prevent vascular damage and cognitive decline.
The APOE4 gene variant increases the risk of Alzheimer's disease by disrupting the insulation of brain wiring. Research found that oligodendrocytes mismanage cholesterol, failing to transport fat molecules to myelinate axons. This deficiency may contribute to the pathology and symptoms of Alzheimer's.
Researchers at University of Cambridge found that a thin shell of water surrounding proteins can determine aggregation, with slower movement leading to more clumping. The discovery has significant implications for treating protein misfolding diseases like Parkinson's and Alzheimer's.
A Rice University bioengineer has developed a noninvasive technology to measure gene expression in deep tissues, particularly in the brain. This innovation could improve the monitoring of gene therapy treating neurodegenerative disorders such as epilepsy, ALS, and Huntington's disease.
Researchers have identified a new gene, NUCL-1, in the transparent roundworm C. elegans, which is linked to human neurodegenerative diseases such as ALS and Alzheimer's. The discovery challenges recent theories on the role of nuclear structures in these disorders.
A new study found that children with four copies of the SMN2 gene who received pre-symptomatic treatment showed no symptoms, while untreated patients developed irreversible symptoms. The researchers recommend encouraging early intervention in childhood for these patients to avoid potential deficits.
Researchers from UCLA have developed a strategy to identify novel treatments for cognitive decline and neurodegenerative diseases by exploiting sex differences in the brain. The study provides a roadmap for disentangling the contribution of sex-specific factors, which can yield treatments optimized for each sex.
A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...
A study published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring found that analyzing patients' speech can distinguish between different types of dementia. The research team developed a machine learning model using speech features to identify Alzheimer's disease and Lewy body dementia.
A study published in the Journal of Alzheimer's Disease found that analyzing patients' drawing tests can help diagnose Alzheimer's disease (AD) and distinguish it from dementia with Lewy bodies (DLB). The researchers discovered that DLB patients showed differences in speed-, pressure-, and pause-related features, whereas AD patients sh...
Researchers have identified a class of lipids called SGDGs that decline in the brain with age and may have anti-inflammatory effects. These findings could lead to new therapeutic interventions for age-related neurological diseases. Further research will be needed to explore the role of SGDGs in human neuroinflammation.
Dr. Louise D. McCullough is being recognized for her groundbreaking research on sex differences in stroke and their impact on immune response, which has led to a greater understanding of the biology behind these differences. Her work has also shed light on the importance of including females in pre-clinical research.
Researchers will investigate immune system differences between men and women to better understand neurodegenerative diseases. The study aims to identify why certain neurological diseases primarily affect males or females, and how this difference impacts disease progression.
A new study by Université Laval researchers has identified a link between insulin receptors in brain microvessels and Alzheimer's disease. The findings suggest that drugs targeting these receptors could be effective in treating the condition, expanding the range of potential treatments.
Scientists at NTU Singapore have found that a stress response in cells, when 'switched on' at a post-reproductive age, could be the key to slowing down aging. The study showed that this stress response extended the lifespan of roundworms fed a high-glucose diet.
A new study aims to diagnose severe neurodegenerative diseases like ALS and FTD with the help of speech tests. AI can analyze subtle nuances of speech patterns, including pauses, speed, and melodic aspects, to detect early changes.
Studies on prion diseases in mice reveal coordinated gene expression changes before symptoms appear, shedding light on selective vulnerability and potential treatment targets. Researchers predict disease progression using new methods, suggesting therapies may be more effective when applied early.
A recent study analyzed the records of over 33,000 dementia patients in Wales and found that those closest to their diagnosis were taking an average of three or more medications. This suggests a possible link between polypharmacy and the development of dementia.
A systematic review and meta-analysis found that psychotic disorders like schizophrenia are associated with a higher risk of developing dementia. People with psychotic disorders are 2.5 times more likely to develop dementia than those without a psychotic disorder, according to the review.
A new CAPSTONE study aims to identify inflammatory biomarkers associated with positive and poor outcomes in patients after intracerebral hemorrhage (ICH) strokes. By analyzing patient blood and plasma samples, researchers hope to develop targeted treatments to prevent long-term brain degeneration.
Scientists have identified long interspersed nuclear element-1 (L1) RNA as a promising new target for treating progeroid syndromes. Increased L1 RNA expression in cells from patients with these disorders led to deactivation of an enzyme, causing cell aging.
Women are more susceptible to Alzheimer's disease due to higher expression of the enzyme ubiquitin-specific peptidase 11 (USP11), which drives increased accumulation of tau protein in brain nerve cells. Researchers hope to develop new neuroprotective medicines based on this finding.
Researchers found mutated PKCγ enzyme leads to elevated activity, disrupting Purkinje cell function and driving cerebellar pathology. The study suggests inhibiting the enzyme may have therapeutic potential for spinocerebellar ataxia type 14 and potentially other subtypes.
Research reveals Alzheimer's disease genomic changes occur primarily in non-neuronal brain cells, rather than neurons. The study found a number of new genes not previously implicated in dementia, which could be targets for future drug development.
The National Institutes of Health has awarded a $10.7 million grant to Cleveland Clinic to expand a national research consortium focused on improving diagnosis and treatments for Dementia with Lewy Bodies. The consortium, which includes multiple clinical sites, aims to identify biomarkers for disease and develop new therapies.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
Researchers have discovered that neurons with double-stranded breaks (DSBs) in their DNA actively trigger an inflammatory response, which is mediated by the activation of the NFkappaB transcription factor. This process elicits an immune response from microglia, leading to synaptic loss and cognitive function impairment.
A University at Buffalo-led study suggests the huntingtin protein is involved in neuronal injury and regeneration. The research found that HTT moves from the injury site to the cell body, carrying components necessary for survival.
A phase 3 clinical trial showed tofersen reduces SOD1 and neurofilament light protein levels, slowing down disease progression. Longer-term use may help stabilize muscle strength and control in people with genetic ALS.
Research findings suggest that aerobic fitness, cognitive processing speed, and walking endurance are strongly associated in individuals with thalamic atrophy. Aerobic exercise training may be beneficial in restoring function for those with this biomarker of neurodegeneration.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
A team of researchers has designed in silico molecular probes to track the progress of a misbehaving protein linked to neurodegenerative diseases like ALS and FTD. The probes can detect TDP-43 aggregates at high resolution, paving the way for early diagnosis.
Researchers established a novel strategy to treat Huntington's disease by converting the disease-causing form of the huntingtin protein into its disease-free form. This process maintains the original function of the protein, offering a new approach to tackle the neurodegenerative disorder.
Researchers have successfully visualized α-synuclein aggregates in the brains of patients with multiple system atrophy (MSA) using a new positron emission tomography (PET) imaging agent. The agent, 18F-SPAL-T-06, shows high specificity and potential for MSA diagnosis.
A team of researchers from Ritsumeikan University in Japan has elucidated the mechanism behind the liquid-solid phase transition of FUS protein that leads to ALS. They discovered a new therapeutic target, arginine, which suppresses FUS aggregation and could delay ALS progression.
A new study reveals that the protein CHIP can regulate insulin receptor signals more efficiently alone than in a paired state. This finding suggests that maintaining a balance between monomeric and dimeric states of CHIP is crucial for proper cellular function.
A new UCLA-led study has identified multiple new risk genes for Alzheimer's disease and progressive supranuclear palsy (PSP) by combining new testing methods. The researchers used high-throughput testing to simultaneously test 5,706 genetic variants in 25 loci associated with Alzheimer's and nine loci associated with PSP.
A KAIST research team has discovered a new role for somatostatin, a protein-based neurotransmitter, in reducing the toxicity caused by Alzheimers disease. When somatostatin is met with copper and Aβ proteins, it attenuates the toxicity and agglomeration of metal-Aβ complexes.
A new study finds that COVID-19 infections may predispose individuals to developing irreversible neurological conditions, such as Alzheimer's and Parkinson's diseases. The research also suggests that the virus can cause long-term neurodegenerative diseases, particularly in the elderly and other vulnerable populations.
A team of researchers has used advanced techniques to identify immature hippocampal neurons in significant numbers throughout the human lifespan. The findings resolve a long-running controversy over adult neurogenesis and provide insights into brain plasticity, memory, mood, behavior, and brain disorders.
Researchers have discovered pairing Spinraza with valproic acid (VPA) can boost its therapeutic effects without increasing toxicity. This approach allows for improved SMN protein production in SMA patients, leading to longer survival and better muscle function.
A new AI technology called in silico FOCUS analyzes cell images to predict therapeutic effect of drugs for neurodegenerative disorders like Kennedy disease. The technology has 100% accuracy and can analyze several hundred thousand cells in just a few minutes.
Researchers at the University of Illinois Urbana-Champaign have developed a low-cost ultrasound imaging method to study the relationship between Alzheimer's disease and the brain's vascular system. The technique, which provides high-resolution images of animal microvasculature, may aid in early detection of the disease.
Researchers found altered cell-mediated immune function in ALS patients and a novel treatment approach using bone marrow transplants. The study suggests that abnormal CD8 T-cell response contributes to motor neuron degeneration.
A recent study published in Movement Disorders found that a buildup of TDP-43 protein may be responsible for PD-related cell death. This discovery suggests a new cause of the disease and could lead to the development of new treatments.
A study by Stephen T. Casper examines how sports slang, such as 'punch-drunk,' influenced the conceptualization and treatment of brain injuries. The research reveals a culture that stigmatized sufferers and normalized male violence, making it difficult for medical professionals to diagnose and treat neurodegenerative disease.
Scientists identify PiT2-loop7 missense mutations causing inorganic phosphate dyshomeostasis, leading to primary familial brain calcification. The study reveals how these mutations affect PiT2 phosphorylation and membrane localization, reducing Pi transport activity.
Researchers from Mount Sinai found a significant connection between the immune system and amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study analyzed mice and human samples using state-of-the-art technologies, revealing peculiar immune signatures that distinguish different forms of ALS.
A new muscle biopsy test could lead to an earlier diagnosis of amyotrophic lateral sclerosis (ALS), a progressive disease affecting nerve cells in the brain and spinal cord. The test targets transactive response DNA-binding protein 43 (TDP-43) accumulation, which may be a biomarker for early ALS diagnosis.
Researchers found that walking enhances performance on cognitive tasks in 14 participants by increasing frontal brain function, while 12 others showed no improvement. This discovery highlights the flexibility of a healthy brain and has implications for understanding aging and neurological disorders.